Guardant Health, Inc. Common Stock (GH) Stock Price
GHStock
$158.60+135.07%52W
Market Cap$21.28B
P/E—
PEG Ratio—
Div yield—
Beta1.71
GH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)73.66%
Price vs S&P 500 (4W)-7.46%
VGM Score56.26
GH Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.39 | -$0.42 | -7.81%(-$0.03) | |
| Q1 2026 | -$0.47 | -$0.45 | +4.97%(+$0.02) | |
| Q4 2025 | -$0.47 | -$0.50 | -6.51%(-$0.03) | |
| Q3 2025 | -$0.49 | -$0.39 | +20.33%(+$0.10) | |
| Q2 2025 | -$0.51 | -$0.44 | +14.54%(+$0.07) |
GH Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.34
4.37
4.34
4.34
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About Guardant Health, Inc. Common Stock
Guardant Health is a liquid biopsy leader providing blood-based cancer tests for clinical detection and monitoring. The company's core franchises include Guardant360 for tumor genomic profiling, Reveal for molecular residual disease monitoring, and Shield for colorectal cancer screening. Guardant also offers regulatory consulting and clinical trial support services for the oncology research market.